If you stop a GLP-1 with no architecture beneath it, two-thirds of the weight comes back within twelve months. The architecture is the program. Drugs are one tool — peptides, hormones, sleep, training, and protein are the rest.
Modern incretin therapy is the most effective metabolic intervention ever made widely available. Tirzepatide produces 20% mean weight loss. Retatrutide will likely produce 28%. These numbers are real and worth respecting.
And yet — the real-world failure mode of GLP-1 therapy is not that the drugs don't work. It is that patients lose weight without an underlying architecture, stop the drug because of cost or side effects, and regain everything plus interest. The 12-month post-discontinuation regain in published trials is roughly two-thirds of total weight lost.
The fix is not "willpower." The fix is building the rest of the system while the drug is doing the heavy lifting. That's what this article is about.
Whether the patient is on tirzepatide, semaglutide, no drug, or a peptide-only protocol, these four pillars are non-negotiable. Drugs amplify what's underneath them. Without these pillars, drugs lose their leverage.
Protein 1.6–2.2 g/kg ideal body weight. Resistance training 3×/week minimum. Creatine 5g daily. Without this, 25–35% of GLP-1 weight loss is lean tissue — unacceptable for longevity.
Testosterone, thyroid, cortisol screened and treated. Untreated hypogonadism caps weight loss in men. Subclinical hypothyroidism slows everything in women. Insulin and glucose optimized in parallel.
7–8 hours of high-quality sleep. Sleep apnea screened and treated (tirzepatide's OSA indication is real). Cortisol and melatonin rhythm coached. No drug overcomes 5 hours of broken sleep nightly.
Discontinuation strategy designed at intake — taper protocols, maintenance dosing, lifestyle anchors. We treat GLP-1s as ongoing therapy unless the patient explicitly chooses otherwise.
These are the tools we deploy alongside (or sometimes instead of) GLP-1s, depending on the patient picture:
FDA-approved GHRH analog. Uniquely targets visceral adipose tissue (VAT) — the metabolically active fat that drives inflammation, insulin resistance, and CV risk. Falutz et al. (Phase 3) demonstrated statistically significant VAT loss at 26 weeks. The most evidence-supported peptide for body recomposition that GLP-1s do not specifically address. Layered onto GLP-1 therapy when scale weight is moving but visceral fat is not.
Mitochondrial-derived peptide. Activates AMPK — the cellular energy sensor central to metabolic flexibility, insulin sensitivity, and endurance. Useful for patients with metabolic plateau, post-GLP-1 maintenance, or longevity-first goals. Returned to legal compounding April 23, 2026.
Pulsatile growth-hormone secretagogue stack. Restores natural GH rhythm lost with age. Improves sleep quality, recovery, and lean-mass preservation — particularly important during a GLP-1 cut. Without HGH-style supraphysiologic spikes or side effects.
Dr. Hare's signature longevity intervention. NAD+ stores deplete with age and accelerate during caloric restriction. Loading protocol restores cellular NAD+ stores; subcutaneous maintenance keeps them there. Affects cognition, recovery, and the rate at which you age. Layered into nearly every Limitless protocol.
Testosterone deficiency caps weight loss. We screen total T, free T, SHBG, LH/FSH, estradiol. Treat to functional/optimal range with cypionate, creams, or pellets — calibrated to the individual. Patients on TRT consistently lose more body fat and preserve more lean mass on GLP-1 therapy than untreated hypogonadal men.
Estradiol, progesterone, and (for many) testosterone optimized to functional ranges. Perimenopausal and post-menopausal weight gain is largely a hormone story; treating the hormones is often more effective than treating the weight.
Recovery and tissue-repair stack. Why it matters for weight loss: increased training volume causes injury risk in patients new to resistance training. BPC-157 + TB-500 keeps you training. Returned to legal Category 1 status April 23, 2026.
Modified GH fragment investigated for fat-loss effects. Less robust evidence base than the peptides above, used selectively for patients with stubborn subcutaneous fat that has not responded to first-line interventions. Not a default add-on. Discussed case-by-case.
Tirzepatide titrated to 10 mg. Testosterone optimized (TRT). MOTS-c 6-week cycle in month 4. NAD+ loading. Resistance training 3×/week with creatine and 1.8 g/kg protein. CGM during the first 90 days for feedback. Plan: 18-month cut, taper, maintenance.
BHRT first (estradiol, progesterone, testosterone). Often, hormone correction alone moves 10–15 lbs over 4 months. If still stuck at month 4, low-dose semaglutide added. Tesamorelin layered for visceral fat. NAD+. Strength training and protein architecture mandatory.
Restart strategy if regain has begun: low-dose tirzepatide as maintenance (often 5 mg). MOTS-c for metabolic re-architecture. Hormone audit. Aggressive resistance training and protein. Goal is not to lose weight — goal is to hold position while building the metabolic chassis that should have been built the first time.
Limitless designs comprehensive weight-loss programs — hormones, peptides, training, nutrition, and (when indicated) GLP-1 therapy — calibrated to your labs, history, and goals. Founding members lock pricing for 24 months.
Book a Consultation Founding Membership